Placebo effects: From the neurobiological paradigm to translational implications

Neuron

Volumn 84, Issue 3, 2014, Pages 623-637

  Benedetti, Fabrizio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; DELTA OPIATE RECEPTOR; DOPAMINE; FATTY ACID AMIDASE; KAPPA OPIATE RECEPTOR; KETOROLAC; MU OPIATE RECEPTOR; OPIATE; PENTAGASTRIN; PLACEBO; PROGLUMIDE; REMIFENTANIL; RIMONABANT;

ANALGESIA; ANTINOCICEPTION; ANXIETY; BRAIN BLOOD FLOW; BRAIN FUNCTION; COGNITION; EMOTION; EXPECTATION; HAWTHORNE EFFECT; HUMAN; INTERPERSONAL COMMUNICATION; LEARNING; MEDICAL ETHICS; MEDICAL PRACTICE; NEUROBIOLOGY; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROSCIENCE; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PARKINSONISM; PHYSICAL PERFORMANCE; PLACEBO EFFECT; REVIEW; SIGNAL TRANSDUCTION; SOCIAL INTERACTION; SOCIAL PHOBIA; ANIMAL; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PROCEDURES; PSYCHOLOGY; TRANSLATIONAL RESEARCH;

ANIMALS; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; NEUROBIOLOGY; PLACEBO EFFECT; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84912125577     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.10.023     Document Type: Review

References (117)

1. Amanzio M., Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J.Neurosci. 1999, 19:484-494.
2. Amanzio M., Pollo A., Maggi G., Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 2001, 90:205-215.
3. Amanzio M., Corazzini L.L., Vase L., Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009, 146:261-269.
4. Amanzio M., Benedetti F., Porro C.A., Palermo S., Cauda F. Activation likelihood estimation meta-analysis of brain correlates of placebo analgesia in human experimental pain. Hum. Brain Mapp. 2013, 34:738-752.
5. Anderson C., Horne J.A. Placebo response to caffeine improves reaction time performance in sleepy people. Hum. Psychopharmacol. 2008, 23:333-336.
6. Andre J., Zeau B., Pohl M., Cesselin F., Benoliel J.J., Becker C. Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies. J.Neurosci. 2005, 25:7896-7904.
7. Atlas L.Y., Whittington R.A., Lindquist M.A., Wielgosz J., Sonty N., Wager T.D. Dissociable influences of opiates and expectations on pain. J.Neurosci. 2012, 32:8053-8064.
8. Bausell R.B., Lao L., Bergman S., Lee W.L., Berman B.M. Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants' perceived assignments in two placebo-controlled trials. Eval. Health Prof. 2005, 28:9-26.
9. Bearman P.S., Moody J. Suicide and friendships among American adolescents. Am. J. Public Health 2004, 94:89-95.
10. Beedie C.J., Foad A.J. The placebo effect in sports performance: a brief review. Sports Med. 2009, 39:313-329.
11. Beedie C.J., Coleman D.A., Foad A.J. Positive and negative placebo effects resulting from the deceptive administration of an ergogenic aid. Int. J. Sport Nutr. Exerc. Metab. 2007, 17:259-269.
12. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996, 64:535-543.
13. Benedetti F. The placebo response: science versus ethics and the vulnerability of the patient. World Psychiatry 2012, 11:70-72.
14. Benedetti F. Placebo and the new physiology of the doctor-patient relationship. Physiol. Rev. 2013, 93:1207-1246.
15. Benedetti F. Responding to nocebos through observation: social contagion of negative emotions. Pain 2013, 154:1165.
16. Benedetti F. Drugs and placebos: what's the difference?: Understanding the molecular basis of the placebo effect could help clinicians to better use it in clinical practice. EMBO Rep. 2014, 15:329-332.
17. Benedetti F. Placebo effects 2014, Oxford University Press, New York. Second Edition.
18. Benedetti F., Frisaldi E. Creating placebo responders and nonresponders in the laboratory: boons and banes. Pain Manag 2014, 4:165-167.
19. Benedetti F., Amanzio M., Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 1995, 346:1231.
20. Benedetti F., Amanzio M., Casadio C., Oliaro A., Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 1997, 71:135-140.
21. Benedetti, F. Maggi, G., Lopiano, L., Lanotte, M., Rainero, I., Vighetti, S., and Pollo, A. (2003a). Open versus hidden medical treatments: the patient's knowledge about a therapy affects the therapy outcome. Prevention & Treatment. http://psycnet.apa.org/journals/pre/6/1/1a/.
22. Benedetti F., Pollo A., Lopiano L., Lanotte M., Vighetti S., Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J.Neurosci. 2003, 23:4315-4323.
23. Benedetti F., Colloca L., Torre E., Lanotte M., Melcarne A., Pesare M., Bergamasco B., Lopiano L. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat. Neurosci. 2004, 7:587-588.
24. Benedetti F., Amanzio M., Vighetti S., Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J.Neurosci. 2006, 26:12014-12022.
25. Benedetti F., Arduino C., Costa S., Vighetti S., Tarenzi L., Rainero I., Asteggiano G. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain 2006, 121:133-144.
26. Benedetti F., Pollo A., Colloca L. Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions?. J.Neurosci. 2007, 27:11934-11939.
27. Benedetti F., Lanotte M., Colloca L., Ducati A., Zibetti M., Lopiano L. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J.Physiol. 2009, 587:3869-3883.
28. Benedetti F., Amanzio M., Thoen W. Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. Psychopharmacology (Berl.) 2011, 213:791-797.
29. Benedetti F., Amanzio M., Rosato R., Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat. Med. 2011, 17:1228-1230.
30. Benedetti F., Carlino E., Pollo A. Hidden administration of drugs. Clin. Pharmacol. Ther. 2011, 90:651-661.
31. Benedetti F., Durando J., Vighetti S. Nocebo and placebo modulation of hypobaric hypoxia headache involves the cyclooxygenase-prostaglandins pathway. Pain 2014, 155:921-928.
32. Bingel U., Lorenz J., Schoell E., Weiller C., Büchel C. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 2006, 120:8-15.
33. Bingel U., Wanigasekera V., Wiech K., Ni Mhuircheartaigh R., Lee M.C., Ploner M., Tracey I. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci. Transl. Med. 2011, 3:70ra14.
34. Büchel C., Geuter S., Sprenger C., Eippert F. Placebo analgesia: a predictive coding perspective. Neuron 2014, 81:1223-1239.
35. Cacioppo J.T., Fowler J.H., Christakis N.A. Alone in the crowd: the structure and spread of loneliness in a large social network. J.Pers. Soc. Psychol. 2009, 97:977-991.
36. Chartrand T.L., Lakin J.L. The antecedents and consequences of human behavioral mimicry. Annu. Rev. Psychol. 2013, 64:285-308.
37. Christakis N.A., Fowler J.H. The spread of obesity in a large social network over 32 years. N.Engl. J. Med. 2007, 357:370-379.
38. Christakis N.A., Fowler J.H. The collective dynamics of smoking in a large social network. N.Engl. J. Med. 2008, 358:2249-2258.
39. Cizza G., Piaggi P., Rother K.I., Csako G. Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies. PLoS ONE 2014, 9:e104176. Sleep Extension Study Group.
40. Colagiuri B., Livesey E.J., Harris J.A. Can expectancies produce placebo effects for implicit learning?. Psychon. Bull. Rev. 2011, 18:399-405.
41. Colloca L., Benedetti F. How prior experience shapes placebo analgesia. Pain 2006, 124:126-133.
42. Colloca L., Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr. Opin. Anaesthesiol. 2007, 20:435-439.
43. Colloca L., Benedetti F. Placebo analgesia induced by social observational learning. Pain 2009, 144:28-34.
44. Colloca L., Lopiano L., Lanotte M., Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol. 2004, 3:679-684.
45. de la Fuente-Fernández R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., Stoessl A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001, 293:1164-1166.
46. de la Fuente-Fernández R., Phillips A.G., Zamburlini M., Sossi V., Calne D.B., Ruth T.J., Stoessl A.J. Dopamine release in human ventral striatum and expectation of reward. Behav. Brain Res. 2002, 136:359-363.
47. Doering B.K., Rief W. Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol. Sci. 2012, 33:165-172.
48. Eippert F., Bingel U., Schoell E.D., Yacubian J., Klinger R., Lorenz J., Büchel C. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009, 63:533-543.
49. Eippert F., Finsterbusch J., Bingel U., Büchel C. Direct evidence for spinal cord involvement in placebo analgesia. Science 2009, 326:404.
50. Enck P., Klosterhalfen S., Weimer K., Horing B., Zipfel S. The placebo response in clinical trials: more questions than answers. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2011, 366:1889-1895.
51. Enck P., Bingel U., Schedlowski M., Rief W. The placebo response in medicine: minimize, maximize or personalize?. Nat. Rev. Drug Discov. 2013, 12:191-204.
52. Epps J., Monk C., Savage S., Marlatt G.A. Improving credibility of instructions in the balanced placebo design: a misattribution manipulation. Addict. Behav. 1998, 23:427-435.
53. Faria V., Appel L., Åhs F., Linnman C., Pissiota A., Frans Ö., Bani M., Bettica P., Pich E.M., Jacobsson E., et al. Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder. Neuropsychopharmacology 2012, 37:2222-2232.
54. Faria V., Åhs F., Appel L., Linnman C., Bani M., Bettica P., Pich E.M., Wahlstedt K., Fredrikson M., Furmark T. Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder. Int. J. Neuropsychopharmacol. 2014, 17:1149-1157.
55. Fava M., Evins A.E., Dorer D.J., Schoenfeld D.A. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother. Psychosom. 2003, 72:115-127.
56. Fowler J.H., Christakis N.A. Dynamic spread of happiness in a large social network: longitudinal analysis over 20 years in the Framingham Heart Study. BMJ 2008, 337:a2338.
57. Fowler J.H., Christakis N.A. Cooperative behavior cascades in human social networks. Proc. Natl. Acad. Sci. USA 2010, 107:5334-5338.
58. Frisaldi E., Carlino E., Lanotte M., Lopiano L., Benedetti F. Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients. Cortex 2013.
59. Furmark T., Appel L., Henningsson S., Ahs F., Faria V., Linnman C., Pissiota A., Frans O., Bani M., Bettica P., et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J.Neurosci. 2008, 28:13066-13074.
60. Goebel M.U., Trebst A.E., Steiner J., Xie Y.F., Exton M.S., Frede S., Canbay A.E., Michel M.C., Heemann U., Schedlowski M. Behavioral conditioning of immunosuppression is possible in humans. FASEB J. 2002, 16:1869-1873.
61. Green M.W., Taylor M.A., Elliman N.A., Rhodes O. Placebo expectancy effects in the relationship between glucose and cognition. Br. J. Nutr. 2001, 86:173-179.
62. Guo J.Y., Wang J.Y., Luo F. Dissection of placebo analgesia in mice: the conditions for activation of opioid and non-opioid systems. J.Psychopharmacol. (Oxford) 2010, 24:1561-1567.
63. Hall K.T., Lembo A.J., Kirsch I., Ziogas D.C., Douaiher J., Jensen K.B., Conboy L.A., Kelley J.M., Kokkotou E., Kaptchuk T.J. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS ONE 2012, 7:e48135.
64. Hashmi J.A., Baria A.T., Baliki M.N., Huang L., Schnitzer T.J., Apkarian A.V. Brain networks predicting placebo analgesia in a clinical trial for chronic back pain. Pain 2012, 153:2393-2402.
65. Jensen K.B., Kaptchuk T.J., Kirsch I., Raicek J., Lindstrom K.M., Berna C., Gollub R.L., Ingvar M., Kong J. Nonconscious activation of placebo and nocebo pain responses. Proc. Natl. Acad. Sci. USA 2012, 109:15959-15964.
66. Kaptchuk T.J. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull. Hist. Med. 1998, 72:389-433.
67. Kaptchuk T.J., Kelley J.M., Conboy L.A., Davis R.B., Kerr C.E., Jacobson E.E., Kirsch I., Schyner R.N., Nam B.H., Nguyen L.T., et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008, 336:999-1003.
68. Kong J., Gollub R.L., Rosman I.S., Webb J.M., Vangel M.G., Kirsch I., Kaptchuk T.J. Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. J.Neurosci. 2006, 26:381-388.
69. Kong J., Kaptchuk T.J., Polich G., Kirsch I., Gollub R.L. Placebo analgesia: findings from brain imaging studies and emerging hypotheses. Rev. Neurosci. 2007, 18:173-190.
70. Krummenacher P., Candia V., Folkers G., Schedlowski M., Schönbächler G. Prefrontal cortex modulates placebo analgesia. Pain 2010, 148:368-374.
71. Last J.M. A dictionary of epidemiology 1983, Oxford University Press, New York.
72. Leuchter A.F., McCracken J.T., Hunter A.M., Cook I.A., Alpert J.E. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J.Clin. Psychopharmacol. 2009, 29:372-377.
73. Levine J.D., Gordon N.C. Influence of the method of drug administration on analgesic response. Nature 1984, 312:755-756.
74. Levine J.D., Gordon N.C., Fields H.L. The mechanism of placebo analgesia. Lancet 1978, 2:654-657.
75. Levine J.D., Gordon N.C., Smith R., Fields H.L. Analgesic responses to morphine and placebo in individuals with postoperative pain. Pain 1981, 10:379-389.
76. Lidstone S.C., Schulzer M., Dinelle K., Mak E., Sossi V., Ruth T.J., de la Fuente-Fernández R., Phillips A.G., Stoessl A.J. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch. Gen. Psychiatry 2010, 67:857-865.
77. Linde K., Witt C.M., Streng A., Weidenhammer W., Wagenpfeil S., Brinkhaus B., Willich S.N., Melchart D. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 2007, 128:264-271.
78. Lui F., Colloca L., Duzzi D., Anchisi D., Benedetti F., Porro C.A. Neural bases of conditioned placebo analgesia. Pain 2010, 151:816-824.
79. Luke D.A., Harris J.K. Network analysis in public health: history, methods, and applications. Annu. Rev. Public Health 2007, 28:69-93.
80. Marlatt G.A., Demming B., Reid J.B. Loss of control drinking in alcoholics: an experimental analogue. J.Abnorm. Psychol. 1973, 81:233-241.
81. McRae C., Cherin E., Yamazaki T.G., Diem G., Vo A.H., Russell D., Ellgring J.H., Fahn S., Greene P., Dillon S., et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch. Gen. Psychiatry 2004, 61:412-420.
82. Meissner K., Bingel U., Colloca L., Wager T.D., Watson A., Flaten M.A. The placebo effect: advances from different methodological approaches. J.Neurosci. 2011, 31:16117-16124.
83. Mitchell S.H., Laurent C.L., de Wit H. Interaction of expectancy and the pharmacological effects of d-amphetamine: subjective effects and self-administration. Psychopharmacology (Berl.) 1996, 125:371-378.
84. Nolan T.A., Price D.D., Caudle R.M., Murphy N.P., Neubert J.K. Placebo-induced analgesia in an operant pain model in rats. Pain 2012, 153:2009-2016.
85. Oken B.S., Flegal K., Zajdel D., Kishiyama S., Haas M., Peters D. Expectancy effect: impact of pill administration on cognitive performance in healthy seniors. J.Clin. Exp. Neuropsychol. 2008, 30:7-17.
86. Pacheco-López G., Niemi M.B., Kou W., Härting M., Fandrey J., Schedlowski M. Neural substrates for behaviorally conditioned immunosuppression in the rat. J.Neurosci. 2005, 25:2330-2337.
87. Parker S., Garry M., Einstein G.O., McDaniel M.A. A sham drug improves a demanding prospective memory task. Memory 2011, 19:606-612.
88. Peciña M., Martínez-Jauand M., Hodgkinson C., Stohler C.S., Goldman D., Zubieta J.K. FAAH selectively influences placebo effects. Mol. Psychiatry 2014, 19:385-391.
89. Petrovic P., Kalso E., Petersson K.M., Ingvar M. Placebo and opioid analgesia- imaging a shared neuronal network. Science 2002, 295:1737-1740.
90. Pollo A., Carlino E., Benedetti F. The top-down influence of ergogenic placebos on muscle work and fatigue. Eur. J. Neurosci. 2008, 28:379-388.
91. Pollo A., Carlino E., Benedetti F. Placebo mechanisms across different conditions: from the clinical setting to physical performance. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2011, 366:1790-1798.
92. Pollo A., Carlino E., Vase L., Benedetti F. Preventing motor training through nocebo suggestions. Eur. J. Appl. Physiol. 2012, 112:3893-3903.
93. Price D.D., Craggs J., Verne G.N., Perlstein W.M., Robinson M.E. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain 2007, 127:63-72.
94. Price D.D., Craggs J.G., Zhou Q.Q., Verne G.N., Perlstein W.M., Robinson M.E. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging. Neuroimage 2009, 47:995-1001.
95. Rief W., Bingel U., Schedlowski M., Enck P. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin. Pharmacol. Ther. 2011, 90:722-726.
96. Rohsenow D.J., Bachorowski J.A. Effects of alcohol and expectancies on verbal aggression in men and women. J.Abnorm. Psychol. 1984, 93:418-432.
97. Ross S., Krugman A.D., Lyerly S.B., Clyde D.J. Drugs and placebos: a model design. Psychol. Rep. 1962, 10:383-392.
98. Schenk L.A., Sprenger C., Geuter S., Büchel C. Expectation requires treatment to boost pain relief: an fMRI study. Pain 2014, 155:150-157.
99. Scott D.J., Stohler C.S., Egnatuk C.M., Wang H., Koeppe R.A., Zubieta J.K. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007, 55:325-336.
100. Scott D.J., Stohler C.S., Egnatuk C.M., Wang H., Koeppe R.A., Zubieta J.K. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch. Gen. Psychiatry 2008, 65:220-231.
101. Servick K. Outsmarting the placebo effect. Science 2014, 345:1446-1447.
102. Smith K.P., Christakis N.A. Social networks and health. Annu. Rev. Sociol. 2008, 34:405-429.
103. Stein N., Sprenger C., Scholz J., Wiech K., Bingel U. White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia. Pain 2012, 153:2210-2217.
104. Stern J., Candia V., Porchet R.I., Krummenacher P., Folkers G., Schedlowski M., Ettlin D.A., Schönbächler G. Placebo-mediated, Naloxone-sensitive suggestibility of short-term memory performance. Neurobiol. Learn. Mem. 2011, 95:326-334.
105. Sutton S.R. Great expectations: some suggestions for applying the balanced placebo design to nicotine and smoking. Br. J. Addict. 1991, 86:659-662.
106. Swider K., Babel P. The effect of the sex of a model on nocebo hyperalgesia induced by social observational learning. Pain 2013, 154:1312-1317.
107. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat. Med. 2010, 16:1277-1283.
108. Vase L., Robinson M.E., Verne G.N., Price D.D. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003, 105:17-25.
109. Vögtle E., Barke A., Kröner-Herwig B. Nocebo hyperalgesia induced by social observational learning. Pain 2013, 154:1427-1433.
110. Volkow N.D., Wang G.J., Ma Y., Fowler J.S., Zhu W., Maynard L., Telang F., Vaska P., Ding Y.S., Wong C., Swanson J.M. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J.Neurosci. 2003, 23:11461-11468.
111. Wager T.D., Rilling J.K., Smith E.E., Sokolik A., Casey K.L., Davidson R.J., Kosslyn S.M., Rose R.M., Cohen J.D. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004, 303:1162-1167.
112. Wager T.D., Scott D.J., Zubieta J.K. Placebo effects on human μ-opioid activity during pain. Proc. Natl. Acad. Sci. USA 2007, 104:11056-11061.
113. Wager T.D., Atlas L.Y., Leotti L.A., Rilling J.K. Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience. J.Neurosci. 2011, 31:439-452.
114. Weger U.W., Loughnan S. Mobilizing unused resources: using the placebo concept to enhance cognitive performance. Q J Exp Psychol (Hove) 2013, 66:23-28.
115. Wilson G.T., Niaura R.S., Adler J.L. Alcohol, selective attention and sexual arousal in men. J.Stud. Alcohol 1985, 46:107-115.
116. Zhang R.R., Zhang W.C., Wang J.Y., Guo J.Y. The opioid placebo analgesia is mediated exclusively through μ-opioid receptor in rat. Int. J. Neuropsychopharmacol. 2013, 16:849-856.
117. Zubieta J.K., Bueller J.A., Jackson L.R., Scott D.J., Xu Y., Koeppe R.A., Nichols T.E., Stohler C.S. Placebo effects mediated by endogenous opioid activity on μ-opioid receptors. J.Neurosci. 2005, 25:7754-7762.